Physician profile
Jane K Jaffe
NPI 1144485152
$12,495.00
in general payments reported to CMS, 2019-2025
37 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,052 · 2021: $1,545 · 2022: $1,702 · 2023: $2,015 · 2024: $2,725 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,160.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,441.01 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Medtronic, INC. | $2,212.47 | 2021-2025 | Interstim |
| Abbvie INC. | $1,983.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $882.41 | 2022-2025 | Dupixent |
| Allergan, INC. | $435.57 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $391.32 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $382.53 | 2020-2025 | Entyvio, Eohilia |
| Medtronic USA, INC. | $373.35 | 2019-2020 | |
| Qol Medical, LLC | $357.57 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $294.16 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $277.94 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $259.28 | 2023-2025 | |
| Genzyme Corporation | $241.32 | 2022-2025 | |
| Conmed Corporation | $168.83 | 2025 | Conmed Hemostasis, Conmed Dilation, Conmed Biliary |
| Gilead Sciences, INC. | $123.82 | 2020-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $117.28 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $109.61 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $98.29 | 2019-2025 | Suflave, Sutab |
| Novo Nordisk INC | $50.63 | 2025 | Wegovy |
| Sandoz INC. | $24.84 | 2025 | Hyrimoz |
| Amgen INC. | $23.69 | 2023 | Avsola |
| Fujifilm Healthcare Americas Corporation | $22.04 | 2021 | |
| Teleflex LLC | $17.98 | 2024 | Solesta |
| Aimmune Therapeutics, INC. | $17.43 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $17.43 | 2025 | Rezdiffra |
| Ge Healthcare | $16.82 | 2025 | |
| Celltrion USA INC. | $16.32 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $16.18 | 2024 | Iqirvo |
| Axonics, INC. | $15.70 | 2022 | |
| Exact Sciences Corporation | $15.14 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $14.10 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.02 | 2020 | |
| Daiichi Sankyo INC. | $13.58 | 2022 | |
| Evoke Pharma, INC. | $13.12 | 2022 | |
| Ucb, INC. | $12.88 | 2019 | |
| Redhill Biopharma INC. | $12.82 | 2021 | |
| Erbe USA INC | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.